Verrica Pharmaceuticals Inc.
HealthcareNASDAQ:VRCA · NASDAQ Global Market
-$0.30 today
Vol 0.05M · Avg 0.09M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-72.3%
avg 12.7%
ROIC
-38.0%
avg -211.2%
ROA
-37.9%
avg -88.6%
Analysis
ROA is currently the strongest return metric at -37.9% versus its period average of -88.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chris Chapman | Chief Commercial Officer | $635,379.00 | — | — | $44,000.00 | 0.41% |
John J. Kirby | Interim Chief Financial Officer | $532,500.00 | — | 54 | $18,962.00 | 0.18% |
Jayson Rieger | President, Chief Executive Officer & Director | $391,167.00 | — | 50 | $512,269.00 | 4.81% |
Noah L. Rosenberg | Chief Medical Officer | $243,316.00 | — | 59 | $233,840.00 | 2.20% |
Bradley J. Catalone | Head of Drug Development | — | — | — | $18,962.00 | 0.18% |
David Zawitz | COO, Chief Legal Officer & Secretary | — | — | 45 | $171,340.00 | 1.61% |
Eugene Scavola | Executive Vice President of Technical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
12
$24.66M
Sells
0
$0.00
Net Sentiment
+$24.66M
Net buying
Most Active
Manning Paul B
4 transactions
1–10 of 12
Analysis
Insiders reported 12 buys worth $24.66M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $24.66M. Manning Paul B was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$161.49M
AN2 Therapeutics, Inc.
NASDAQ:ANTX
$129.89M
Generation Bio Co.
GBIO
$35.98M
Mural Oncology plc
MURA
$35.38M
SAB Biotherapeutics, Inc.
SABS
$31.83M
Boundless Bio, Inc.
BOLD
$31.67M
Evaxion Biotech A/S
EVAX
$22.99M
Plus Therapeutics, Inc.
PSTV
$12.12M
Jasper Therapeutics, Inc.
JSPR
$7.44M
NextCure, Inc.
NXTC
$5.56M
Who manages VRCA?
Verrica Pharmaceuticals Inc. (VRCA) lists 7 active executives. The top listed executive is Jayson Rieger, President, Chief Executive Officer & Director.
Are VRCA insiders buying or selling?
Recent insider activity shows net buying of $147.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.